Windtree Therapeutics Inc. has announced receiving a deficiency letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For the past 30 consecutive business days, the company's common stock has closed below the required $1.00 per share threshold. While companies typically have 180 days to rectify such deficiencies, Windtree is under a Discretionary Panel Monitor until March 2026. This situation arises as the company has conducted two reverse stock splits in the last two years, totaling a ratio of over 250 to one. Windtree plans to request a hearing before a Nasdaq Hearings Panel by June 25, 2025, which will temporarily stay any suspension or delisting actions. However, there is no guarantee that the company will be granted an extension or regain compliance. Currently, Windtree's stock continues to trade under the symbol "WINT."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.